Genmab A/S (NASDAQ:GMAB) Stock Holdings Lifted by Crossmark Global Holdings Inc.

Crossmark Global Holdings Inc. lifted its stake in shares of Genmab A/S (NASDAQ:GMAB) by 8.8% in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 41,622 shares of the company’s stock after acquiring an additional 3,377 shares during the quarter. Crossmark Global Holdings Inc.’s holdings in Genmab A/S were worth $868,000 at the end of the most recent reporting period.

A number of other hedge funds have also modified their holdings of GMAB. GAMMA Investing LLC lifted its holdings in shares of Genmab A/S by 96.6% during the fourth quarter. GAMMA Investing LLC now owns 2,139 shares of the company’s stock valued at $45,000 after purchasing an additional 1,051 shares during the last quarter. Blue Trust Inc. grew its position in Genmab A/S by 892.0% during the 3rd quarter. Blue Trust Inc. now owns 4,315 shares of the company’s stock worth $108,000 after purchasing an additional 3,880 shares in the last quarter. Allspring Global Investments Holdings LLC raised its stake in Genmab A/S by 43.6% during the 3rd quarter. Allspring Global Investments Holdings LLC now owns 4,653 shares of the company’s stock valued at $113,000 after purchasing an additional 1,413 shares during the period. Benjamin F. Edwards & Company Inc. lifted its holdings in shares of Genmab A/S by 7.1% in the second quarter. Benjamin F. Edwards & Company Inc. now owns 7,227 shares of the company’s stock valued at $182,000 after purchasing an additional 478 shares in the last quarter. Finally, Mount Yale Investment Advisors LLC acquired a new stake in shares of Genmab A/S in the third quarter worth $192,000. 7.07% of the stock is currently owned by institutional investors and hedge funds.

Genmab A/S Stock Down 0.8 %

NASDAQ GMAB opened at $21.13 on Friday. The stock has a market capitalization of $13.98 billion, a PE ratio of 20.51, a price-to-earnings-growth ratio of 0.57 and a beta of 0.97. Genmab A/S has a 12-month low of $19.85 and a 12-month high of $31.88. The company has a 50 day moving average price of $21.07 and a two-hundred day moving average price of $23.96.

Genmab A/S (NASDAQ:GMAB) last released its quarterly earnings data on Wednesday, November 6th. The company reported $0.29 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.32 by ($0.03). Genmab A/S had a net margin of 23.49% and a return on equity of 14.64%. The business had revenue of $816.10 million during the quarter, compared to analyst estimates of $838.20 million. During the same period in the previous year, the firm posted $0.47 EPS. As a group, equities analysts anticipate that Genmab A/S will post 1.28 EPS for the current year.

Analysts Set New Price Targets

GMAB has been the topic of several recent analyst reports. BMO Capital Markets reissued an “outperform” rating and set a $48.00 price target (up from $46.00) on shares of Genmab A/S in a research report on Friday, November 8th. HC Wainwright reiterated a “buy” rating and issued a $50.00 target price on shares of Genmab A/S in a report on Thursday. Redburn Atlantic assumed coverage on shares of Genmab A/S in a report on Tuesday, October 8th. They set a “buy” rating for the company. Finally, Sanford C. Bernstein upgraded shares of Genmab A/S from a “strong sell” rating to a “hold” rating in a research note on Friday, December 20th. Three equities research analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. Based on data from MarketBeat, Genmab A/S has a consensus rating of “Moderate Buy” and a consensus price target of $45.20.

About Genmab A/S

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.